Lila Adnane
About
In The Last Decade
Lila Adnane
6 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 101
- Molecular Biology 1.1k
- Oncology 1.0k
- Hepatology 659
- Pulmonary and Respiratory Medicine 582
- Pathology and Forensic Medicine 522
Countries citing papers authored by Lila Adnane
This map shows the geographic impact of Lila Adnane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lila Adnane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lila Adnane more than expected).
Fields of papers citing papers by Lila Adnane
This network shows the impact of papers produced by Lila Adnane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lila Adnane. The network helps show where Lila Adnane may publish in the future.
Co-authorship network of co-authors of Lila Adnane
This figure shows the co-authorship network connecting the top 25 collaborators of Lila Adnane. A scholar is included among the top collaborators of Lila Adnane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lila Adnane. Lila Adnane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 49 | |
| 3 | Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity breakdown → | 1025 |
| 4 | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling breakdown → | 1146 |
| 5 | Preclinical characterization of BAY 73-4506: A kinase inhibitor with broad spectrum antitumor activity targeting oncogenic and angiogenic kinases | 5 |
| 6 | 37 | |
| 7 | 371 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.